Cannabinoid CB 2 receptors: A therapeutic target for the treatment of inflammatory and neuropathic pain

British Journal of Pharmacology

Volumn 153, Issue 2, 2008, Pages 319-334

  Guindon, J ^a   Hohmann, A G ^a  

^a University of Georgia ^*  (United States)

Author keywords

Allodynia; Central sensitization; Endocannabinoid; Hyperalgesia; Nerve injury

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 2 METHYL 3 (2 MORPHOLINOETHYL) 5 METHOXYINDOLE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DRONABINOL; ENZYME INHIBITOR; GW 405833; GW 842166; PACLITAXEL; RIMONABANT; UNCLASSIFIED DRUG; URB 602; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT;

BEHAVIORAL SCIENCE; DRUG ANTAGONISM; DRUG BINDING; DRUG EFFECT; DRUG INHIBITION; DRUG STRUCTURE; ELECTROPHYSIOLOGY; NERVE CELL; NERVE INJURY; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG POTENTIATION; HUMAN; INFLAMMATION; PERIPHERAL NEUROPATHY;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATION; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; RECEPTOR, CANNABINOID, CB2;

EID: 38349119715     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707531     Document Type: Review

References (103)

1. Baumann TK, Simone DA, Shain CN, LaMotte RH (1991). Neurogenic hyperalgesia: the search for the primary cutaneous afferent fibers that contribute to capsaicin-induced pain and hyperalgesia. J Neurophysiol 66: 212-227.
2. 2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 23: 1530-1538.
3. 2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol 151: 1061-1070.
4. 2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem 237: 704-711.
5. Bridges D, Ahmad K, Rice AS (2001). The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 133: 586-594.
6. 2 receptor. Eur J Pharmacol 396: 141-149.
7. Calignano A, La Rana G, Giuffrida A, Piomelli D (1998). Control of pain initiation by endogenous cannabinoids. Nature 394: 277-281.
8. Calignano A, La Rana G, Piomelli D (2001). Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 419: 191-198.
9. Cantón A, Fernández Castañer M, Conget I, Carreras G, Castell C, Tresserras R (2004). Type 1 diabetes mellitus in Catalonia: chronic complications and metabolic control ten years after onset. Med Sci Monit 10: CR185-CR190.
10. Choong KC, Su X, Urban MO (2007). Effect of CP55,940 on mechanosensory spinal neurons following chronic inflammation. Neurosci Lett 414: 105-109.
11. 2 cannabinoid receptors are implicated in inflammatory pain. Pain 96: 253-260.
12. Coderre TJ, Katz J (1997). Peripheral and central hyperexcitability: differential signs and symptoms in persistent pain. Behav Brain Sci 20: 404-419; discussion 435-513.
13. Coderre TJ, Melzack R (1992). The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury. J Neurosci 12: 3665-3670.
14. DeLeo JA, Yezierski RP (2001). The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 90: 1-6.
15. De Petrocellis L, Bisogno T, Ligresti A, Bifulco M, Melck D, Di Marzo V (2002). Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam Clin Pharmacol 16: 297-302.
16. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949.
17. Di Marzo V, De Petrocellis L (2006). Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med 57: 553-574.
18. Dubner R, Ren K (1999). Assessing transient and persistent pain in animals. In: Wall PD, Melzack R (eds). Textbook of Pain 4th edn. Churchill Livingstone: New York and Hong Kong, pp 359-369.
19. Dyson A, Peacock M, Chen A, Courade JP, Yaqoob M, Groarke A et al. (2005). Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain 116: 129-137.
20. 2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci 20: 2311-2320.
21. 2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain 118: 327-335.
22. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 92: 3376-3380.
23. 2 receptors. Mol Pharmacol 48: 443-450.
24. Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L et al. (2001). The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92: 91-100.
25. Gallant M, Dufresne C, Gareau Y, Guay D, Leblanc Y, Prasit P et al. (1996). New class of potent ligands for human peripheral cannabinoid receptor. Bioorg Med Chem Lett 6: 2263-2268.
26. Galiègue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P et al. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232: 54-61.
27. Gaoni Y, Mechoulam R (1971). The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc 93: 217-224.
28. Gatley SJ, Lan R, Pyatt B, Gifford AN, Volkow ND, Makriyannis A (1997). Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci 61: PL 191-PL 197.
29. 2 receptor agonist for the treatment of inflammatory pain. J Med Chem 50: 2597-2600.
30. Gilchrist HD, Allard BL, Simone DA (1996). Enhanced withdrawal responses to heat and mechanical stimuli following intraplantar injection of capsaicin in rats. Pain 67: 179-188.
31. 2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol 339: 53-61.
32. 2 cannabinoid receptor. J Pharmacol Exp Ther 292: 886-894.
33. Guindon J, Beaulieu P (2006). Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain. Neuropharmacology 50: 814-823.
34. Guindon J, De Léan A, Beaulieu P (2006). Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. Pain 121: 85-93.
35. 2 receptors. Br J Pharmacol 150: 693-701.
36. Guindon J, Lo Verme J, De Léan A, Piomelli D, Beaulieu P (2007b). Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides? Eur J Pharmacol 550: 68-77.
37. Guindon J, Walczak JS, Beaulieu P (2007). Recent advances in the pharmacological management of pain. Drugs 67: 2121-2133.
38. 2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol 150: 153-163.
39. 2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96: 14228-14233.
40. Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988). A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32: 77-88.
41. Herzberg U, Eliav E, Bennett GJ, Kopin IJ (1997). The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 221: 157-160.
42. Hohmann AG (2002). Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids 121: 173-190.
43. 2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther 308: 446-453.
44. 2 receptors suppresses chemotherapeutic neuropathy evoked by paclitaxel and vincristine administration. Eur J Pain 11 (Suppl 1): S121.
45. Honore P, Chapman V, Buritova J, Besson JM (1995). When is the maximal effect of pre-administered systemic morphine on carrageenin evoked spinal c-Fos expression in the rat? Brain Res 705: 91-96.
46. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ (2004). Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47: 345-358.
47. 2 receptor. Curr Pharm Des 6: 1323-1337.
48. 2 receptor. Bioorg Med Chem 7: 2905-2914.
49. 2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100: 10529-10533.
50. 2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 102: 3093-3098.
51. 2 cannabinoid receptor mediation of antinociception. Pain 122: 36-42.
52. 2 receptor selective agonist JWH133 reduces mast cell oedema in response to compound 48/80 in vivo but not the release of β-hexosaminidase from skin slices in vitro. Life Sci 78: 598-606.
53. Kim SH, Chung JM (1992). An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50: 355-363.
54. 2 receptor agonist activity in the hindpaw incision model of postoperative pain. Eur J Pharmacol 527: 172-174.
55. LaMotte RH, Lundberg LE, Torebjörk HE (1992). Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin. J Physiol (Lond) 448: 749-764.
56. Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D et al. (1999). Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 42: 769-776.
57. LoVerme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A et al. (2005). The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67: 15-19.
58. LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G et al. (2006). Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther 319: 1051-1061.
59. 2 cannabinoid receptor-mediated peripheral antinociception. Pain 93: 239-245.
60. 2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 95: 437-445.
61. Martin WJ, Patrick AL, Coffin PO, Tsou K, Walker JM (1995). An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci 56: 2103-2109.
62. Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A (1996). N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol 300: 227-236.
63. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90.
64. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65.
65. 2 receptors suppresses spinal Fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 119: 747-757.
66. Nackley AG, Suplita II RL, Hohmann AG (2003b). A peripheral cannabinoid mechanism suppresses spinal Fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 117: 659-670.
67. 2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol 92: 3562-3574.
68. Palmer SL, Thakur GA, Makriyannis A (2002). Cannabinergic ligands. Chem Phys Lipids 121: 3-19.
69. Pertwee RG (2001). Cannabinoid receptors and pain. Prog Neurobiol 63: 569-611.
70. Pertwee R, Griffin G, Fernando S, Li X, Hill A, Makriyannis A (1995). AM630, a competitive cannabinoid receptor antagonist. Life Sci 56: 1949-1955.
71. Polomano RC, Bennett GJ (2001). Chemotherapy-evoked painful peripheral neuropathy. Pain Med 2: 8-14.
72. 2, cannabinoid receptors. Br J Pharmacol 150: 519-525.
73. Puig S, Sorkin LS (1996). Formalin-evoked activity in identified primary afferent fibers: systemic lidocaine suppresses phase-2 activity. Pain 64: 345-355.
74. 2 cannabinoid receptors. Anesthesiology 99: 955-960.
75. 2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol 152: 765-777.
76. Ren K, Dubner R (1999). Inflammatory models of pain and hyperalgesia. ILAR J 40: 111-118.
77. Rinaldi-Carmona M, Barth F, Héaulme M, Alonso R, Shire D, Congy C et al. (1995). Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56: 1941-1947.
78. 2 cannabinoid receptor. J Pharmacol Exp Ther 284: 644-650.
79. Romero-Sandoval A, Eisenach JC (2007). Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision. Anesthesiology 106: 787-794.
80. 2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 126: 665-672.
81. Ross RA, Coutts AA, McFarlane SM, Anavi-Goffer S, Irving AJ, Pertwee RG et al. (2001). Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology 40: 221-232.
82. 2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur J Neurosci 22: 371-379.
83. 2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain 109: 124-131.
84. Seltzer Z, Dubner R, Shir Y (1990). A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 43: 205-218.
85. Serra J, Campero M, Bostock H, Ochoa J (2004). Two types of C nociceptors in human skin and their behavior in areas of capsaicin-induced secondary hyperalgesia. J Neurophysiol 91: 2770-2781.
86. 2: identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278: 989-999.
87. Siau C, Bennett GJ (2006). Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy. Anesth Analg 102: 1485-1490.
88. Slipetz DM, O'Neill GP, Favreau L, Dufresne C, Gallant M, Gareau Y et al. (1995). Activation of the human peripheral cannabinoid receptor results in inhibtion of adenylyl cyclase. Mol Pharmacol 48: 352-361.
89. Tjölsen A, Berge OG, Hunskaar S, Rosland JH, Hole K (1992). The formalin test: an evaluation of the method. Pain 51: 5-17.
90. Torebjörk HE, Lundberg LE, LaMotte RH (1992). Central changes in processing of mechanoreceptive input in capsaicin-induced secondary hyperalgesia in humans. J Physiol (Lond) 448: 765-780.
91. Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gootshall SL et al. (2005). Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48: 658-672.
92. 2 receptors. Science 310: 329-332.
93. Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P (2005). Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. Neuroscience 132: 1093-1102.
94. Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P (2006). Characterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changes. J Neurosci Res 83: 1310-1322.
95. Walker JM, Hohmann AG (2005). Cannabinoid mechanisms of pain suppression. In: Pertwee R (ed). Cannabinoids- Handbook of Experimental Pharmacology. Springer-Verlag: Berlin. pp 509-554.
96. Walker KM, Urban L, Medhurst SJ, Patel S, Panesar M, Fox AJ et al. (2003). The VR1 antagonist capsazepine reverses mechanical hyperalgesiain models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 304: 56-62.
97. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G et al. (2003). Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23: 1398-1405.
98. Weng H-R, Cordella JV, Dougherty PM (2003). Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia. Pain 103: 131-138.
99. 2-selective agonist, GW405833. Eur J Pharmacol 528: 65-72.
100. Wotherspoon G, Fox A, McIntyre P, Colley S, Bevan S, Winter J (2005). Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135: 235-245.
101. 2 receptor? Br J Pharmacol 149: 145-154.
102. 2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17: 2750-2754.
103. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999). Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB receptor knockout mice. Proc Natl Acad Sci USA 96: 5780-5785.